SEC Filing Summary

Richard Nolan, the Chief Executive Officer of Lexeo Therapeutics, Inc., reported a series of transactions on September 24, 2026. He acquired 145,500 stock options with an exercise price of $3.39, vesting partially on September 24, 2027, and the remainder monthly thereafter. Additionally, Nolan acquired 2,306 shares of common stock under the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan at $2.644 per share. Following these transactions, his post-transaction holdings include 376,778 shares of common stock, which incorporates 242,911 Restricted Stock Units.